EA201790949A1 - Замещенные 2,4-диаминохинолины в качестве новых противораковых средств - Google Patents

Замещенные 2,4-диаминохинолины в качестве новых противораковых средств

Info

Publication number
EA201790949A1
EA201790949A1 EA201790949A EA201790949A EA201790949A1 EA 201790949 A1 EA201790949 A1 EA 201790949A1 EA 201790949 A EA201790949 A EA 201790949A EA 201790949 A EA201790949 A EA 201790949A EA 201790949 A1 EA201790949 A1 EA 201790949A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diaminochinolines
facilities
cancer
substituted
new anti
Prior art date
Application number
EA201790949A
Other languages
English (en)
Other versions
EA037119B1 (ru
Inventor
Фира Бассисси
Антуан БЕРЕ
Сонья Брен
Жером Куркамбек
Кларисс Дюбре
Грегори Николя
Филипп Альфон
Original Assignee
Дженосайенс Фарма
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дженосайенс Фарма filed Critical Дженосайенс Фарма
Publication of EA201790949A1 publication Critical patent/EA201790949A1/ru
Publication of EA037119B1 publication Critical patent/EA037119B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Настоящее изобретение относится к новым производным 2-первичный амино-4-вторичный амино-хинолина, их получению, фармацевтическим композициям, содержащим их, и их применению в качестве лекарственных средств. Активные соединения по настоящему изобретению пригодны для лечения и профилактики пролиферативных неопластических и ненеопластических заболеваний.
EA201790949A 2014-10-31 2015-10-26 Замещенные 2,4-диаминохинолины в качестве новых противораковых средств EA037119B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462073325P 2014-10-31 2014-10-31
PCT/IB2015/002438 WO2016067112A1 (en) 2014-10-31 2015-10-26 Substituted 2,4 diamino-quinoline as new anticancer agents

Publications (2)

Publication Number Publication Date
EA201790949A1 true EA201790949A1 (ru) 2018-02-28
EA037119B1 EA037119B1 (ru) 2021-02-09

Family

ID=55404745

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790949A EA037119B1 (ru) 2014-10-31 2015-10-26 Замещенные 2,4-диаминохинолины в качестве новых противораковых средств

Country Status (34)

Country Link
US (1) US10722505B2 (ru)
EP (1) EP3212629B1 (ru)
JP (1) JP6588546B2 (ru)
KR (1) KR102548547B1 (ru)
CN (1) CN107148416B (ru)
AU (1) AU2015338844B2 (ru)
CA (1) CA2965262C (ru)
CL (1) CL2017001073A1 (ru)
CO (1) CO2017007325A2 (ru)
CR (1) CR20170177A (ru)
CY (1) CY1121326T1 (ru)
DK (1) DK3212629T3 (ru)
DO (1) DOP2017000107A (ru)
EA (1) EA037119B1 (ru)
EC (1) ECSP17026748A (ru)
ES (1) ES2707125T3 (ru)
GE (1) GEP20207108B (ru)
HR (1) HRP20190107T1 (ru)
IL (1) IL251775B (ru)
LT (1) LT3212629T (ru)
MA (1) MA40875B1 (ru)
MY (1) MY193740A (ru)
NI (1) NI201700052A (ru)
PE (1) PE20191142A1 (ru)
PH (1) PH12017500810A1 (ru)
PL (1) PL3212629T3 (ru)
PT (1) PT3212629T (ru)
RS (1) RS58328B1 (ru)
SG (1) SG11201703479SA (ru)
SI (1) SI3212629T1 (ru)
TN (1) TN2017000168A1 (ru)
TR (1) TR201900148T4 (ru)
UA (1) UA122062C2 (ru)
WO (1) WO2016067112A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6969800B2 (ja) * 2016-05-04 2021-11-24 ジェノシアンス ファルマ 増殖性疾患の治療に使用される置換２，４−ジアミノ−キノリン誘導体
US11065265B2 (en) 2018-05-18 2021-07-20 Spes Pharmaceuticals Inc. Compositions of fosaprepitant and methods of preparation
EP3620164A1 (en) * 2018-09-05 2020-03-11 Genoscience Pharma SAS Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins b (ctsb), l (ctsl) and d (ctsd) related diseases
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
JP7460644B2 (ja) 2018-10-31 2024-04-02 ギリアード サイエンシーズ， インコーポレイテッド Ｈｐｋ１阻害剤としての置換６－アザベンゾイミダゾール化合物
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
WO2022033459A1 (zh) * 2020-08-10 2022-02-17 萧乃文 双非癌药物用于制备治疗癌症的医药组合物的用途
CN112375081B (zh) * 2020-11-23 2022-04-12 中国医学科学院医药生物技术研究所 具有抑制CDK4、6或9活性的吡咯[2,3-d]嘧啶衍生物及其制备方法和应用
CN112876673B (zh) * 2021-01-25 2021-12-24 山东大学 一种pH响应性纳米共聚物载体及其制备方法和应用
EP4349336A1 (en) 2022-10-04 2024-04-10 Genoscience Pharma Combination of substituted 2,4 diamino-quinoline compounds and mek inhibitors for use in the treatment of liver cancers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8580301A1 (es) * 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
WO2004052862A1 (ja) * 2002-12-10 2004-06-24 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途
JP2006519846A (ja) * 2003-03-10 2006-08-31 シェーリング　コーポレイション 複素環式キナーゼインヒビター：使用および合成の方法
NZ710079A (en) * 2013-01-15 2020-01-31 Incyte Holdings Corp Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
WO2014147611A1 (en) * 2013-03-18 2014-09-25 Genoscience Pharma Quinolines derivatives as novel anticancer agents

Also Published As

Publication number Publication date
UA122062C2 (uk) 2020-09-10
LT3212629T (lt) 2019-01-10
NZ731345A (en) 2023-09-29
CN107148416B (zh) 2020-05-05
TN2017000168A1 (en) 2018-10-19
NI201700052A (es) 2017-09-11
US20190314359A1 (en) 2019-10-17
CA2965262C (en) 2023-03-14
MA40875A (fr) 2017-09-06
PT3212629T (pt) 2019-02-04
HRP20190107T1 (hr) 2019-03-08
CL2017001073A1 (es) 2018-01-12
WO2016067112A1 (en) 2016-05-06
KR102548547B1 (ko) 2023-06-27
CY1121326T1 (el) 2020-05-29
DK3212629T3 (en) 2019-02-18
DOP2017000107A (es) 2017-09-15
SI3212629T1 (sl) 2019-02-28
IL251775A0 (en) 2017-06-29
CA2965262A1 (en) 2016-05-06
BR112017018637A2 (pt) 2022-07-05
PE20191142A1 (es) 2019-09-02
CR20170177A (es) 2017-09-19
KR20170077160A (ko) 2017-07-05
MA40875B1 (fr) 2019-01-31
RS58328B1 (sr) 2019-03-29
CN107148416A (zh) 2017-09-08
SG11201703479SA (en) 2017-05-30
JP6588546B2 (ja) 2019-10-09
JP2017538673A (ja) 2017-12-28
GEAP202014494A (en) 2020-01-27
AU2015338844A1 (en) 2017-05-04
MY193740A (en) 2022-10-27
GEP20207108B (en) 2020-05-11
AU2015338844B2 (en) 2019-09-19
IL251775B (en) 2020-07-30
ECSP17026748A (es) 2018-03-31
PL3212629T3 (pl) 2019-05-31
EA037119B1 (ru) 2021-02-09
US10722505B2 (en) 2020-07-28
ES2707125T3 (es) 2019-04-02
CO2017007325A2 (es) 2017-10-20
TR201900148T4 (tr) 2019-02-21
EP3212629A1 (en) 2017-09-06
PH12017500810A1 (en) 2017-10-02
EP3212629B1 (en) 2018-10-24

Similar Documents

Publication Publication Date Title
EA201790949A1 (ru) Замещенные 2,4-диаминохинолины в качестве новых противораковых средств
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
PH12016501898A1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201792047A1 (ru) Новые соединения
MX2015013396A (es) Derivados de quinolinas como nuevos agentes contra el cancer.
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201592068A1 (ru) Ингибиторы энхансера zeste гомолога 2
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
TW201613864A (en) Novel compounds
EA201792057A1 (ru) Конденсированные бициклические гетероарильные производные с активностью ингибиторов пролилгидроксилазы
TW201613909A (en) Benzoxazinone amides as mineralocorticoid receptor modulators
EA202190588A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата
EA201892539A1 (ru) Пиридинильные производные, фармацевтические композиции и их применение в качестве ингибиторов аос3
EA201891680A1 (ru) Производные индана в качестве модуляторов mglur7
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
EA201790795A1 (ru) СОЕДИНЕНИЯ 4Н-ПИРИДО[1,2-a]ПИРИМИДИН-4-ОНА
MX2018003564A (es) 1,4-benzodiazepinas biheteroarilo sustituidas y usos de las mismas para el tratamiento del cancer.
EA201891136A1 (ru) Фармацевтическая композиция, содержащая в качестве активного ингредиента производное 7-азаиндолин-2-она или его фармацевтически приемлемую соль